224 related articles for article (PubMed ID: 24927959)
21. Risk assessment for Japanese encephalitis vaccination.
Turtle L; Driver C
Hum Vaccin Immunother; 2018 Jan; 14(1):213-217. PubMed ID: 29244615
[TBL] [Abstract][Full Text] [Related]
22. A chimeric live attenuated vaccine against Japanese encephalitis.
Jones T
Expert Rev Vaccines; 2004 Jun; 3(3):243-8. PubMed ID: 15176941
[TBL] [Abstract][Full Text] [Related]
23. Past, present, and future of Japanese encephalitis.
Erlanger TE; Weiss S; Keiser J; Utzinger J; Wiedenmayer K
Emerg Infect Dis; 2009 Jan; 15(1):1-7. PubMed ID: 19116041
[TBL] [Abstract][Full Text] [Related]
24. Travel-acquired Japanese encephalitis and vaccination considerations.
Pavli A; Maltezou HC
J Infect Dev Ctries; 2015 Sep; 9(9):917-24. PubMed ID: 26409731
[TBL] [Abstract][Full Text] [Related]
25. Partial cross-protection between Japanese encephalitis virus genotype I and III in mice.
Wei J; Wang X; Zhang J; Guo S; Pang L; Shi K; Liu K; Shao D; Qiu Y; Liu L; Widén F; Li B; Ma Z
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007601. PubMed ID: 31374086
[TBL] [Abstract][Full Text] [Related]
26. Japanese encephalitis virus: Associated immune response and recent progress in vaccine development.
Kumar A; Sharma P; Shukla KK; Misra S; Nyati KK
Microb Pathog; 2019 Nov; 136():103678. PubMed ID: 31437579
[TBL] [Abstract][Full Text] [Related]
27. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
[TBL] [Abstract][Full Text] [Related]
28. [The progress and challenge of Japanese encephalitis control and prevention in China].
Wang HY
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Feb; 53(2):133-135. PubMed ID: 30744284
[TBL] [Abstract][Full Text] [Related]
29. Japanese encephalitis vaccines: moving away from the mouse brain.
Zanin MP; Webster DE; Martin JL; Wesselingh SL
Expert Rev Vaccines; 2003 Jun; 2(3):407-16. PubMed ID: 12903806
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan.
Yang SE; Pan MJ; Tseng HF; Liau MY
Vaccine; 2006 Mar; 24(14):2669-73. PubMed ID: 16314007
[TBL] [Abstract][Full Text] [Related]
31. New Japanese encephalitis vaccines: alternatives to production in mouse brain.
Halstead SB; Thomas SJ
Expert Rev Vaccines; 2011 Mar; 10(3):355-64. PubMed ID: 21434803
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
[TBL] [Abstract][Full Text] [Related]
33. Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO
Amicizia D; Zangrillo F; Lai PL; Iovine M; Panatto D
J Prev Med Hyg; 2018 Mar; 59(1):E99-E107. PubMed ID: 29938245
[TBL] [Abstract][Full Text] [Related]
34. Japanese encephalitis: new options for active immunization.
Halstead SB; Thomas SJ
Clin Infect Dis; 2010 Apr; 50(8):1155-64. PubMed ID: 20218889
[TBL] [Abstract][Full Text] [Related]
35. Japanese encephalitis vaccine for travelers: exploring the limits of risk.
Shlim DR; Solomon T
Clin Infect Dis; 2002 Jul; 35(2):183-8. PubMed ID: 12087525
[TBL] [Abstract][Full Text] [Related]
36. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
37. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
[TBL] [Abstract][Full Text] [Related]
38. Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.
Okamoto S; Yoshii H; Matsuura M; Kojima A; Ishikawa T; Akagi T; Akashi M; Takahashi M; Yamanishi K; Mori Y
Clin Vaccine Immunol; 2012 Jan; 19(1):17-22. PubMed ID: 22089248
[TBL] [Abstract][Full Text] [Related]
39. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
[TBL] [Abstract][Full Text] [Related]
40. Current recommendations for the Japanese encephalitis vaccine.
Chen HL; Chang JK; Tang RB
J Chin Med Assoc; 2015 May; 78(5):271-5. PubMed ID: 25841620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
